Ingeborg van Leeuwen
Cited by
Cited by
Chaste: a test-driven approach to software development for biological modelling
J Pitt-Francis, P Pathmanathan, MO Bernabeu, R Bordas, J Cooper, ...
Computer Physics Communications 180 (12), 2452-2471, 2009
An integrative computational model for intestinal tissue renewal
IMM Van Leeuwen, GR Mirams, A Walter, A Fletcher, P Murray, J Osborne, ...
Cell proliferation 42 (5), 617-636, 2009
Crypt dynamics and colorectal cancer: advances in mathematical modelling
IMM Van Leeuwen, HM Byrne, OE Jensen, JR King
Cell proliferation 39 (3), 157-181, 2006
Sirtuins and p53
I van Leeuwen, S Lain
Advances in cancer research 102, 171-195, 2009
A DHODH inhibitor increases p53 synthesis and enhances tumor cell killing by p53 degradation blockage
MJGW Ladds, IMM Van Leeuwen, CJ Drummond, S Chu, AR Healy, ...
Nature communications 9 (1), 1107, 2018
Evaluation of an Actinomycin D/VX-680 aurora kinase inhibitor combination in p53-based cyclotherapy
B Rao, IMM van Leeuwen, M Higgins, J Campbell, AM Thompson, ...
Oncotarget 1 (7), 639, 2010
Elucidating the interactions between the adhesive and transcriptional functions of β-catenin in normal and cancerous cells
IMM van Leeuwen, HM Byrne, OE Jensen, JR King
Journal of theoretical biology 247 (1), 77-102, 2007
Modelling microbial adaptation to changing availability of substrates
BW Brandt, FDL Kelpin, IMM van Leeuwen, SALM Kooijman
Water research 38 (4), 1003-1013, 2004
Towards a multiscale model of colorectal cancer
IMM Van Leeuwen, CM Edwards, M Ilyas, HM Byrne
World journal of gastroenterology: WJG 13 (9), 1399, 2007
A general model for multiple substrate biodegradation. Application to co-metabolism of structurally non-analogous compounds
BW Brandt, IMM van Leeuwen, SALM Kooijman
Water research 37 (20), 4843-4854, 2003
An evaluation of small-molecule p53 activators as chemoprotectants ameliorating adverse effects of anticancer drugs in normal cells
IMM van Leeuwen, B Rao, MCC Sachweh, S Laín
Cell cycle 11 (9), 1851-1861, 2012
Mechanism-specific signatures for small-molecule p53 activators
IMM van Leeuwen, M Higgins, J Campbell, CJ Brown, AR McCarthy, ...
Cell cycle 10 (10), 1590-1598, 2011
Dynamic energy budget approaches for modelling organismal ageing
IMM van Leeuwen, J Vera, O Wolkenhauer
Philosophical Transactions of the Royal Society B: Biological Sciences 365 …, 2010
Modulation of p53 C-Terminal Acetylation by mdm2, p14ARF, and Cytoplasmic SirT2
IMM van Leeuwen, M Higgins, J Campbell, AR McCarthy, MCC Sachweh, ...
Molecular cancer therapeutics 12 (4), 471-480, 2013
SysBioMed report: advancing systems biology for medical applications
O Wolkenhauer, D Fell, P De Meyts, N Blüthgen, H Herzel, N Le Novere, ...
IET systems biology 3 (3), 131-136, 2009
Tenovin-D3, a Novel Small-Molecule Inhibitor of Sirtuin SirT2, Increases p21 (CDKN1A) Expression in a p53-Independent Manner
AR McCarthy, MCC Sachweh, M Higgins, J Campbell, CJ Drummond, ...
Molecular cancer therapeutics 12 (4), 352-360, 2013
Systems biologists seek fuller integration of systems biology approaches in new cancer research programs
O Wolkenhauer, C Auffray, S Baltrusch, N Blüthgen, H Byrne, M Cascante, ...
Cancer research 70 (1), 12-13, 2010
A mathematical model that accounts for the effects of caloric restriction on body weight and longevity
IMM Van Leeuwen, FDL Kelpin, S Kooijman
Biogerontology 3, 373-381, 2002
Cyclotherapy: opening a therapeutic window in cancer treatment
IMM van Leeuwen
Oncotarget 3 (6), 596, 2012
From exposure to effect: a comparison of modeling approaches to chemical carcinogenesis
IMM van Leeuwen, C Zonneveld
Mutation Research/Reviews in Mutation Research 489 (1), 17-45, 2001
The system can't perform the operation now. Try again later.
Articles 1–20